Feedback / Questions
odronextamab (REGN1979) - Regeneron
Odronextamab: BLA submission for B-cell NHL in H2 2023
(Regeneron Pharmaceuticals)
-
May 4, 2023 -
Q1 2023 Results
BLA
•
Non-Hodgkin's Lymphoma • Oncology
https://investor.regeneron.com/static-files/dbe7aad3-8aff-483f-9366-fa1678d7b738
May 4, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious